Engineered Botulinum Neurotoxin Light Chain for Non-Neuronal SNARE Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current botulinum neurotoxins (BoNTs) are limited in their therapeutic utility to neuron-related diseases due to their specificity for neuronal SNARE proteins, making them ineffective for treating non-neuronal secretion disorders.
Innovation Solution
Genetically engineered botulinum neurotoxins with mutated light chains that exhibit improved binding and substrate specificity for non-neuronal SNARE proteins, such as SNAP-23 and SNAP-29, are developed, allowing for targeted secretion inhibition in non-neuronal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If botulinum neurotoxins are used to block secretion, then neurotransmitter release from motor neurons is inhibited, but they cannot effectively treat non-neuronal secretion disorders due to specificity for neuronal SNARE proteins
Solution Approach 1:
The patent applies local quality by modifying specific regions of the botulinum neurotoxin molecule, particularly the light chain portion, to alter its substrate specificity. The modification enables the toxin to recognize and cleave non-neuronal SNARE proteins (such as SNAP-23 and SNAP-29) while maintaining its ability to bind and enter target cells, thus adapting the toxin's function for non-neuronal applications without losing its core mechanism of action
Solution Approach 2:
The patent employs parameter changes by systematically varying amino acid sequences in the botulinum neurotoxin light chain to optimize binding affinity and cleavage efficiency for non-neuronal SNARE proteins. Through mutagenesis and selection processes, specific parameter changes in the toxin's structure result in improved effectiveness for treating non-neuronal secretion disorders while maintaining selective toxicity
2Adaptability or versatility
If botulinum neurotoxins are engineered to target non-neuronal SNARE proteins, then therapeutic utility expands to non-neuronal diseases, but proteolytic specificity for neuronal SNARE proteins is reduced
Solution Approach 1:
The patent applies local quality by making targeted modifications to specific regions of the botulinum neurotoxin light chain that are responsible for substrate recognition and cleavage. These localized changes enable the toxin to recognize non-neuronal SNARE proteins while minimizing alterations to other functional domains, thus maintaining a degree of substrate specificity even as the target scope expands
Solution Approach 2:
The patent uses an intermediary approach by engineering botulinum neurotoxins with modified light chains that serve as intermediates between the original neuronal-specific toxins and the desired non-neuronal targeting capability. These engineered toxins act as mediators that can selectively target non-neuronal SNARE proteins through optimized binding interfaces and cleavage sites, bridging the gap between neuronal and non-neuronal applications
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified botulinum neurotoxins provide specific and long-lasting control of hyper-secretion from non-neuronal cells, effectively treating diseases associated with elevated secretory activity.
Implementation Method 1
the L chain portion of the molecule is released and degrades the targeted SNARE protein required for controlled neurotransmitter secretion in a highly sequence-specific manner
Data Source
AI summary
Methods for treating diseases characterized by elevated secretory activity using a protease directed to a non-neuronal SNARE protein are described. The protease is produced by selective mutation of a botulinum neurotoxin light chain, and is characterized utilizing a reporting construct that includes all or part of the non-neuronal SNARE protein. Such a protease has utility in the treatment of diseases associated with hypersecretion, where the hypersecretion is mediated by a non-neuronal SNARE protein.